The Food and Drug Administration on Friday approved Celgene’s drug Abraxane for use in treating advanced pancreatic cancer, supplementing the thin arsenal available to fight the disease.
In a clinical trial, Abraxane prolonged the lives of patients by a little less than two months on average. Pancreatic specialists have said the drug was a welcome, if modest, advance against a disease that is extremely tough to treat.
http://www.nytimes.com/2013/09/07/business/fda-approves-drug-for-late-stage-pancreatic-cancer.html?smid=pl-share
No comments:
Post a Comment